US equities
|
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
SPCX
$147.49
▲+0.00%
TSLA
$372.22
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
SNDK
$1,238.03
▲+0.00%
MELI
$1,810.15
▲+0.00%
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
SPCX
$147.49
▲+0.00%
TSLA
$372.22
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
SNDK
$1,238.03
▲+0.00%
MELI
$1,810.15
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Personalis
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
April 26, 2022
From
Personalis
Via
Business Wire
Tickers
EVAX
PSNL
Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development
August 25, 2021
From
Personalis
Via
Business Wire
Tickers
PSNL